<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424436</url>
  </required_header>
  <id_info>
    <org_study_id>113043</org_study_id>
    <nct_id>NCT01424436</nct_id>
  </id_info>
  <brief_title>Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient</brief_title>
  <official_title>Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild
      Alzheimer's disease or mild cognitive impairment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, an open label, single dose and parallel group study to assess short term
      pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be
      assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of
      GSK933776 by i.v. administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2010</start_date>
  <completion_date type="Actual">December 8, 2011</completion_date>
  <primary_completion_date type="Actual">December 8, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The temporal changes of amyloid beta levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment</measure>
    <time_frame>22 hours</time_frame>
    <description>To compare the changes of amyloid beta levels between the baseline (9 hours) and after single dose of GSK933776 iv administration of 13 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The temporal changes of total and free amyloid beta levels in plasma after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment</measure>
    <time_frame>Two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The temporal changes of Tau and phosphor Tau - 181 levels in CSF after GSK933776 single dose administration in the patients with Alzheimer's disease and Mild Cognitive impairment</measure>
    <time_frame>22 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated pharmacokinetic parameters of AUC, Cmax and Tmax in CSF and plasma at multiple time points with various intervals.</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability after single dose of GSK933776 administration.</measure>
    <time_frame>three months</time_frame>
    <description>The safety and tolerability measures are performed at screening, dosing day and follow up. The assessments included: • Adverse event reporting and safety laboratory data. • CNS Safety: MRI and MMSE. • CVS safety: ECG and vital signs. •Anti-GSK933776 antibodies.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>GSK933776 1mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK933776 0.1 or 3mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK933776 3 or 6mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK933776</intervention_name>
    <description>1mg/kg dose group</description>
    <arm_group_label>GSK933776 1mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK933776</intervention_name>
    <description>3mg/kg dose group</description>
    <arm_group_label>GSK933776 0.1 or 3mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK933776</intervention_name>
    <description>6mg/kg dose group</description>
    <arm_group_label>GSK933776 3 or 6mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Probable mild Alzheimer's disease (MMSE 20-26) or mild cognitive impairment

          -  Increase in total tau or p-tau in CSF

          -  Decrease in amyloid beta in CSF

          -  Stable dose of cholinesterase inhibitors, memantine or selegine or no treatment

          -  Body weight less than 120 kg

          -  Willingness to comply with contraceptive methods if self or partner is of
             child-bearing potential

        Exclusion Criteria:

          -  Any other cause of dementia

          -  Other significant neurologic or psychiatric illness

          -  Hachinski Ischemia Score &gt;4

          -  More than 3 microbleeds on MRI

          -  Type 2 diabetes not controlled by diet

          -  Risk of cerebrovascular disease, cerebral haemorrhage or stroke

          -  History of systemic autoimmune disease

          -  Use of platelet anti-aggregates or anti-coagulants (Aspirin up to 325 mg/day is
             allowable)

          -  Use of chronic corticosteroids

          -  Uncontrolled hypertension in spite of antihypertensive medications

          -  Renal or hepatic insufficiency or clinically significant anaemia

          -  In nursing home care

          -  Contraindications to lumbar puncture or MRI

          -  Prior participation in therapeutic studies only after adequate wash-out period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-212 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>se-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/113043?search=study&amp;search_terms=113043#rs</url>
    <description>Results for study 113043 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CSF sampling</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Amyloid beta levels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113043</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113043</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113043</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113043</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113043</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113043</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113043</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

